BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Gene therapy efforts active, despite low Bluebird, 2seventy bids
Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30 million for...

More in BioWorld

BioWorld MedTech

Liquid biopsy market flooded with opportunity
With an at least $60 billion total addressable market, the liquid biopsy sector offers abundant opportunity for multiple companies to swim to the top. The six largest...

More in BioWorld MedTech

BioWorld Science

Genes and Epstein-Barr virus immune response increase MS risk
A combination of Epstein-Barr virus (EBV) antibodies and genetic factors may be linked to an increased risk of multiple sclerosis (MS), according to a study led by...

More in BioWorld Science

BioWorld Asia

Kyowa Kirin, Amgen’s rocatinlimab ignites positive response in Rocket study
Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to...

More in BioWorld Asia

BioWorld Insider Podcast

Billion-dollar biopharma mergers fall short of the dream: Karen Carey, BioWorld’s senior managing editor and chief analyst, crunched the numbers on 21 of the biggest M&As and found very few have been, so far, good deals for the buyer.